尿激酶
链激酶
血栓
肺栓塞
组织纤溶酶原激活剂
心脏病学
纤溶酶原激活剂
医学
内科学
药理学
心肌梗塞
出处
期刊:Protein and Peptide Letters
[Bentham Science]
日期:2019-10-14
卷期号:27 (2): 111-119
被引量:16
标识
DOI:10.2174/0929866526666191014150408
摘要
: An imbalance in oxygen supply to cardiac tissues or formation of thrombus leads to deleterious results like pulmonary embolism, coronary heart disease and acute cardiac failure. The formation of thrombus requires clinical encounter with fibrinolytic agents including streptokinase, urokinase or tissue plasminogen activator. Irrespective to urokinase and tissue plasminogen activator, streptokinase is still a significant agent in treatment of cardiovascular diseases. Streptokinase, being so economical, has an important value in treating cardiac diseases in developing countries. This review paper will provide the maximum information to enlighten all the pros and cons of streptokinase up till now. It has been concluded that recent advances in structural/synthetic biology improved SK with enhanced half-life and least antigenicity. Such enzyme preparations would be the best thrombolytic agents.
科研通智能强力驱动
Strongly Powered by AbleSci AI